Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Amit K Verma
Albert Einstein College of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Kansas Cancer Center
Kansas City, Kansas, United States
- Albert Einstein College of Medicine
The Bronx, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2012
- Primary completion
- 9 Jul 2020
- Completion
- 9 Jul 2020
- Last update posted
- 27 Jul 2023
- Registered enrollment
- 52
- Registry id
- NCT01772420
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.